Product logins

Find logins to all Clarivate products below.


Autism Spectrum Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Autism Spectrum Disorder (US)

Autism spectrum disorder (ASD) is a complex, heterogeneous, neurodevelopmental disorder that involves significant social, communicational, and behavioral challenges. Behavioral and developmental therapies are the cornerstones of treatment. There is no cure for ASD, and pharmacological intervention is mainly focused on symptomatic management. Risperidone and aripiprazole are the only two FDA-approved drugs for the treatment of irritability associated with ASD; other drugs, such as antidepressants, stimulants, and antiepileptics, are used off-label to manage co-occurring psychiatric conditions. Our Treatment Algorithms study provides national patient-level claims data to explore the use of key therapies in both newly diagnosed and recently treated patients, providing insight into the current treatment landscape for ASD.

Questions answered

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed ASD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed ASD patients?
  • How have atypical antipsychotics been integrated into the treatment algorithm, and what is their source of business?
  • What percentage of ASD patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of ASD patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall, using real-world, patient-level claims data, enabling you to:

  • Understand patient flow between lines of therapy.
  • Evaluate your brand share against competitors.
  • Accurately assess your source of business.
  • Quantify opportunities at different stages of the treatment algorithm.

Product enhancement

Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.

Content highlights

Publication date: April 2026

Geography: United States

Real-world data: U.S. pharmacy and medical claims data

Key drugs covered: Risperidone, aripiprazole, sertraline, methylphenidate HCl, fluoxetine

Key analyses:

  • Brand / therapy usage across longitudinal patient sample
  • Newly diagnosed patient analysis
  • Treatment initiation and progression
  • Line of therapy analysis
  • Combination therapy analysis
  • Source of business for recently treated patients
  • Persistency and compliance analysis
  • Product-level patient flow

Related Market Assessment Reports

Report
Major Depressive Disorder (DSM-V) – Landscape & Forecast – Disease Landscape & Forecast (Major Markets)
The major depressive disorder (MDD) therapy market is crowded and highly genericized. Extensive use of generic agents—particularly selective serotonin reuptake inhibitors (SSRIs) as earlyline…
Report
Gene Therapy – Access & Reimbursement – Access & Reimbursement – Gene Therapies for Rare Diseases (US)
With the increasing number of approved innovative, high-cost gene therapies, value assessment and novel reimbursement approaches are rapidly gaining importance. To assist developers of gene…
Report
Colorectal Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
Doublet or triplet chemotherapy, alone or in combination with angiogenesis inhibitors, remains the cornerstone of treatment for metastatic colorectal cancer. Patients without RAS or BRAF mutations…
Report
Hidradenitis Suppurativa – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hidradenitis Suppurativa (US)
Hidradenitis suppurativa (HS) is a chronic, relapsing inflammatory disorder of the hair follicles, characterized by painful, inflamed lesions often filled with fluid or pus. AbbVie’s Humira (…
Report
Squamous Cell Carcinoma of the Head and Neck – Landscape & Forecast – Disease Landscape & Forecast (Major Markets)
Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and…